Glucokinase activator for treating diabetes with renal impairment
US11857536B2 · kind B2 · utility
0Cited by
2References
45Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 3, 2021 |
| Grant date | Jan 2, 2024 |
| Priority date | — |
| Expiry date | Aug 7, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a glucokinase-mediated disorder, disease, or condition in a renally impaired subject with a glucokinase activator (GKA), for example, dorzagliatin. Also provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a diabetes in a renally impaired subject with a GKA. Additionally, provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a chronic kidney disease with a GKA.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.